A Phase III, Randomized, Double-blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, In Patients with Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

Despite recent advances in first-line treatment of HCC, there remains a need for novel therapeutic approaches that target mechanisms of resistance to cancer immunotherapy, provide more durable clinical benefit, and improve long-term survival outcomes. Higher levels of TIGIT, an immune receptor, have been associated with poor clinical outcomes by resisting cancer immunotherapy. This anti-TIGIT monoclonal antibody may augment anticancer therapies, in this case atezolizumab and bevacizumab, that would have otherwise been resisted.

Criteria:

  • Locally advanced or metastatic and/or unresectable liver cancer (HCC)
  • No prior systemic treatment for locally advanced or metastatic and/or unresectable HCC
  • Adequate hematologic and end-organ function

Locations: Hartford Hospital, Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut, MidState Medical Center

Contacts: Hartford Region - [email protected] 860-972-5518, Central Region - [email protected] 860-696-4958

Sponsors: F. Hoffman-La Roche

Cancer Clinical Research Office